Asset 1

Biotech

We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.

With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.

Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.

We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.

Sciences de la vie et Santé

Long-running issue: the distinction between cosmetic products and medicinal products by function

15 décembre 2022
Briefing

par Dr. Manja Epping et Sherin Sayed

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Federal Social Court: High barriers for cannabis on health insurance prescription

13 décembre 2022
Quick read

par Dr. Daniel Tietjen

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

OLG Frankfurt am Main: Distribution of free drug samples to pharmacists

13 décembre 2022
Quick read

par Dr. Daniel Tietjen

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

ECJ: Requirements for the repackaging of medicinal products in view of the new anti-counterfeiting regulations

13 décembre 2022
Briefing

par Dr. Daniel Tietjen

Cliquer ici pour en savoir plus

Événements connexes